CONMED Company Profile (NASDAQ:CNMD)


CONMED logoCONMED Corporation is a medical technology company. The Company is engaged in the development, manufacturing and sale on a global basis of surgical devices and related equipment. The Company provides surgical devices and equipment for minimally invasive procedures. The Company's products are used by surgeons and physicians in a range of specialties, including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. The Company's product lines consist of orthopedic surgery, general surgery and surgical visualization. As of December 31, 2016, the Company's products are distributed domestically directly to over 6,000 hospitals, surgery centers and other healthcare institutions, as well as through medical specialty distributors. The Company's orthopedic surgery product lines include sports medicine, powered surgical instruments, and sports biologics and tissue. These products are marketed under a range of brands, including Hall, CONMED Linvatec, Concept and Shutt.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NASDAQ:CNMD
  • CUSIP: 20741010
  • Web:
  • Market Cap: $1.41 billion
  • Outstanding Shares: 27,871,000
Average Prices:
  • 50 Day Moving Avg: $48.28
  • 200 Day Moving Avg: $44.75
  • 52 Week Range: $37.60 - $51.50
  • Trailing P/E Ratio: 115.15
  • Foreward P/E Ratio: 24.54
  • P/E Growth: 4.32
Sales & Book Value:
  • Annual Revenue: $768.89 million
  • Price / Sales: 1.83
  • Book Value: $20.65 per share
  • Price / Book: 2.45
  • Annual Dividend: $0.80
  • Dividend Yield: 1.6%
  • EBIDTA: $124.94 million
  • Net Margins: 1.92%
  • Return on Equity: 8.38%
  • Return on Assets: 3.65%
  • Debt-to-Equity Ratio: 0.84%
  • Current Ratio: 2.90%
  • Quick Ratio: 1.71%
  • Average Volume: 153,148 shs.
  • Beta: 0.77
  • Short Ratio: 8.46

Frequently Asked Questions for CONMED (NASDAQ:CNMD)

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Wednesday, May 24th. Shareholders of record on Thursday, June 15th will be paid a dividend of $0.20 per share on Wednesday, July 5th. This represents a $0.80 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date is Tuesday, June 13th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) released its quarterly earnings results on Wednesday, April, 26th. The company reported $0.38 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.35 by $0.03. The business earned $186.57 million during the quarter, compared to analyst estimates of $181.47 million. CONMED had a return on equity of 8.38% and a net margin of 1.92%. The firm's quarterly revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.42 EPS. View CONMED's Earnings History.

When will CONMED make its next earnings announcement?

CONMED is scheduled to release their next quarterly earnings announcement on Tuesday, July, 25th 2017. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY17 earnings guidance on Wednesday, April, 26th. The company provided earnings per share guidance of $1.85-1.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.89.

Where is CONMED's stock going? Where will CONMED's stock price be in 2017?

3 brokerages have issued 12-month target prices for CONMED's stock. Their predictions range from $43.00 to $54.00. On average, they expect CONMED's share price to reach $48.33 in the next twelve months. View Analyst Ratings for CONMED.

What are analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:

  • 1. According to Zacks Investment Research, "Over the past six months CONMED Corporation has outperformed the broader industry trends in terms of price performance. However, a falling estimate revision trend for the current year indicates looming concerns ahead of the stock. The company has recently registered strong first-quarter results wherein adjusted earnings beat the Zacks Consensus Estimate, while revenues also did the same. Foreign exchange movements have been unfavorably impacting the company’s results of late. Additionally, the company operates in a highly competitive environment which is likely to mar the top-line growth. Declining sales in the Orthopaedic surgery surgical visualization segment, especially in the U.S. in the last reported quarter is an added concern." (4/28/2017)
  • 2. Needham & Company LLC analysts commented, "CNMD’s 1Q17 revenue and EPS beat consensus and management maintained its 2017 guidance. Importantly, CNMD’s revenue growth (arguably the most important metric at this point) improved to 3.7% CC in 1Q17 from (1.5%) CC in 4Q16. This is the highest organic growth CNMD has seen in the past six years. While comps get a bit more difficult in the next few quarters, new products (particularly in the Orthopedic Surgery business) should begin to meaningfully contribute to growth by 2H17." (4/27/2017)
  • 3. Leerink Swann analysts commented, "We remain cautious on the company’s ability to manage through what we believe could be meaningful top-line headwinds in F2H17 and FY2018 in order to return to and sustain a solid mid- single-digit growth trajectory after just 3% growth in F2Q17, including: (1) A competitive CRM (cardiac rhythm management) product cycle, (2) Current and upcoming competitive launches in DES (drug eluting stents), (3) Potential modest share loss in U.S. TAVR (transcatheter aortic valve replacement) with a competitor recently receiving an expanded indication that is likely ~12-18 months ahead of MDT only partially offset by MDT’s recent large valve size launch; and (4) Continued share loss in Neuromodulation, particularly in SCS (spinal cord stimulation), DBS (deep brain stimulation), and implantable drug infusion pumps." (11/23/2016)

Who are some of CONMED's key competitors?

Who owns CONMED stock?

CONMED's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (11.31%), Dimensional Fund Advisors LP (8.41%), Vanguard Group Inc. (8.14%), Victory Capital Management Inc. (7.72%), Champlain Investment Partners LLC (6.20%) and Goldman Sachs Group Inc. (3.61%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, David M Bronson, Heather L Cohen, Jerome J Lande, Jo Ann Golden, John L Workman, Luke A Pomilio, Mark D Snyder, Mark E Tryniski and Stephen Mandia. View Institutional Ownership Trends for CONMED.

Who sold CONMED stock? Who is selling CONMED stock?

CONMED's stock was sold by a variety of institutional investors in the last quarter, including Granahan Investment Management Inc. MA, Morgan Stanley, JPMorgan Chase & Co., Fisher Asset Management LLC, Goldman Sachs Group Inc., Westwood Holdings Group Inc., Netols Asset Management Inc. and United Services Automobile Association. Company insiders that have sold CONMED stock in the last year include Daniel Jonas and Luke A Pomilio. View Insider Buying and Selling for CONMED.

Who bought CONMED stock? Who is buying CONMED stock?

CONMED's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Victory Capital Management Inc., Champlain Investment Partners LLC, Epoch Investment Partners Inc., Macquarie Group Ltd., Vanguard Group Inc., Citadel Advisors LLC and State Street Corp. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, David M Bronson, Heather L Cohen, John L Workman and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy CONMED stock?

Shares of CONMED can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of CONMED stock cost?

One share of CONMED stock can currently be purchased for approximately $50.55.

Analyst Ratings

Consensus Ratings for CONMED (NASDAQ:CNMD) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $48.33 (4.39% downside)

Analysts' Ratings History for CONMED (NASDAQ:CNMD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
4/27/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$50.00 -> $48.00HighView Rating Details
4/27/2017Needham & Company LLCBoost Price TargetBuy -> Buy$48.00 -> $54.00HighView Rating Details
11/23/2016Leerink SwannReiterated RatingHold -> NeutralN/AView Rating Details
11/17/2015Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/22/2015Northland SecuritiesLower Price TargetMarket Perform$58.00 -> $44.00N/AView Rating Details
8/27/2015Piper Jaffray CompaniesReiterated RatingNeutral$51.00N/AView Rating Details
(Data available from 5/25/2015 forward)


Earnings History for CONMED (NASDAQ:CNMD)
Earnings by Quarter for CONMED (NASDAQ:CNMD)
Earnings History by Quarter for CONMED (NASDAQ:CNMD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2017Q1 2017$0.35$0.38$181.47 million$186.57 millionViewN/AView Earnings Details
2/1/2017Q416$0.56$0.54$204.04 million$204.10 millionViewListenView Earnings Details
10/27/2016Q316$0.41$0.41$180.13 million$184.79 millionViewListenView Earnings Details
7/27/2016Q216$0.46$0.47$191.48 million$193.40 millionViewListenView Earnings Details
4/27/2016Q116$0.41$0.42$180.15 million$181.20 millionViewListenView Earnings Details
1/27/2016Q415$0.51$0.52$191.03 million$191.00 millionViewListenView Earnings Details
10/21/2015Q315$0.44$0.38$173.96 million$169.20 millionViewListenView Earnings Details
7/21/2015Q215$0.44$0.36$182.40 million$181.00 millionViewListenView Earnings Details
4/22/2015Q115$0.41$0.42$176.16 million$177.90 millionViewListenView Earnings Details
1/27/2015Q414$0.54$0.53$196.00 million$195.00 millionViewListenView Earnings Details
10/23/2014Q314$0.39$0.44$173.30 million$175.00 millionViewListenView Earnings Details
7/23/2014Q214$0.47$0.47$190.62 million$188.20 millionViewListenView Earnings Details
4/24/2014Q1$0.47$0.49$191.95 million$181.90 millionViewListenView Earnings Details
2/13/2014Q413$0.49$0.53$197.24 million$203.40 millionViewListenView Earnings Details
10/24/2013Q313$0.40$0.40$186.20 million$179.30 millionViewListenView Earnings Details
7/24/2013Q2 2013$0.44$0.43$193.55 million$193.00 millionViewListenView Earnings Details
4/25/2013Q1 2013$0.45$0.45$196.79 million$187.00 millionViewListenView Earnings Details
2/14/2013Q4 2012$0.50$0.52$200.12 million$201.20 millionViewListenView Earnings Details
10/25/2012$0.40$0.43ViewN/AView Earnings Details
7/26/2012$0.45$0.43ViewN/AView Earnings Details
4/26/2012$0.44$0.43ViewN/AView Earnings Details
2/15/2012$0.39$0.46ViewN/AView Earnings Details
10/27/2011$0.31$0.33ViewN/AView Earnings Details
7/28/2011$0.35$0.35ViewN/AView Earnings Details
4/28/2011$0.31$0.37ViewN/AView Earnings Details
2/3/2011$0.36$0.36ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for CONMED (NASDAQ:CNMD)
2017 EPS Consensus Estimate: $1.86
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172$0.30$0.37$0.34
Q2 20172$0.41$0.44$0.43
Q3 20172$0.43$0.44$0.44
Q4 20172$0.65$0.68$0.67
(Data provided by Zacks Investment Research)


Current Dividend Information for CONMED (NASDAQ:CNMD)
Next Dividend:7/5/2017
Annual Dividend:$0.80
Dividend Yield:1.58%
Payout Ratio:153.85% (Trailing 12 Months of Earnings)
42.78% (Based on This Year's Estimates)
38.83% (Based on Next Year's Estimates)
Dividend Payments by Quarter for CONMED (NASDAQ:CNMD)

Dividend History by Quarter for CONMED (NASDAQ:CNMD)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for CONMED (NASDAQ:CNMD)
Insider Ownership Percentage: 1.91%
Insider Trades by Quarter for CONMED (NASDAQ:CNMD)
Institutional Ownership by Quarter for CONMED (NASDAQ:CNMD)
Insider Trades by Quarter for CONMED (NASDAQ:CNMD)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/15/2017Daniel JonasEVPSell3,000$51.22$153,660.00View SEC Filing  
4/3/2017Charles FarkasDirectorBuy180$44.41$7,993.80View SEC Filing  
3/13/2017Heather L CohenEVPBuy440$40.00$17,600.00View SEC Filing  
3/10/2017Curt R HartmanCEOBuy8,030$40.11$322,083.30View SEC Filing  
3/6/2017Mark E TryniskiDirectorBuy5,000$41.15$205,750.00View SEC Filing  
1/3/2017Charles FarkasDirectorBuy305$44.65$13,618.25View SEC Filing  
11/8/2016Daniel JonasEVPSell1,500$41.78$62,670.00View SEC Filing  
11/7/2016Daniel JonasEVPSell2,555$40.40$103,222.00View SEC Filing  
10/3/2016Charles FarkasDirectorBuy336$40.04$13,453.44View SEC Filing  
7/1/2016Charles FarkasDirectorBuy282$47.87$13,499.34View SEC Filing  
6/3/2016Luke A PomilioCFOSell4,400$41.56$182,864.00View SEC Filing  
4/1/2016Charles FarkasDirectorBuy338$42.04$14,209.52View SEC Filing  
3/4/2016Mark D SnyderEVPSell2,940$41.32$121,480.80View SEC Filing  
3/2/2016John L WorkmanDirectorBuy2,500$39.85$99,625.00View SEC Filing  
2/19/2016Jerome J LandeDirectorSell1,630,800$38.28$62,427,024.00View SEC Filing  
1/4/2016Charles FarkasDirectorBuy332$42.18$14,003.76View SEC Filing  
12/11/2015David M BronsonDirectorBuy1,500$41.01$61,515.00View SEC Filing  
6/12/2015Jo Ann GoldenDirectorSell1,000$56.03$56,030.00View SEC Filing  
5/29/2015Stephen MandiaDirectorSell14,000$55.62$778,680.00View SEC Filing  
5/6/2015Pat BeyerInsiderBuy5,000$53.36$266,800.00View SEC Filing  
4/30/2015Stephen MandiaDirectorSell3,899$49.97$194,833.03View SEC Filing  
12/12/2014Stephen MandiaDirectorSell4,500$43.23$194,535.00View SEC Filing  
12/1/2014Dirk KuyperDirectorSell1,000$42.85$42,850.00View SEC Filing  
11/19/2014Joseph G DarlingEVPSell4,270$42.00$179,340.00View SEC Filing  
10/29/2014Robert D Shallish JrCFOSell10,410$41.67$433,784.70View SEC Filing  
9/4/2014William AbrahamEVPSell16,062$39.91$641,034.42View SEC Filing  
8/26/2014William AbrahamEVPSell7,423$38.36$284,746.28View SEC Filing  
8/21/2014William AbrahamEVPSell15,986$37.71$602,832.06View SEC Filing  
8/19/2014William AbrahamEVPSell5,312$37.75$200,528.00View SEC Filing  
7/31/2014Curt R HartmanCEOBuy10,000$39.25$392,500.00View SEC Filing  
7/30/2014Bruce DanielsDirectorSell1,600$39.31$62,896.00View SEC Filing  
7/30/2014Joseph J CorasantiCEOSell109,035$39.25$4,279,623.75View SEC Filing  
10/29/2013Joseph J CorasantiCEOSell80,148$36.47$2,922,997.56View SEC Filing  
10/28/2013Bruce DanielsDirectorSell4,500$36.43$163,935.00View SEC Filing  
9/13/2013Joseph CorasantiCEOSell44,852$33.04$1,481,910.08View SEC Filing  
9/11/2013William AbrahamSVPSell7,423$33.48$248,522.04View SEC Filing  
8/15/2013Dirk KuyperDirectorBuy1,000$31.63$31,630.00View SEC Filing  
6/7/2013Daniel JonasVPSell2,000$32.42$64,840.00View SEC Filing  
6/4/2013Heather L CohenVPSell1,200$32.59$39,108.00View SEC Filing  
5/31/2013Luke A PomilioVPSell2,556$33.19$84,833.64View SEC Filing  
5/29/2013Heather L CohenVPSell4,514$34.31$154,875.34View SEC Filing  
5/28/2013Robert D Shallish JrCFOSell10,000$34.35$343,500.00View SEC Filing  
2/15/2013Stuart J SchwartzDirectorSell1,000$30.32$30,320.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for CONMED (NASDAQ:CNMD)
Latest Headlines for CONMED (NASDAQ:CNMD)
DateHeadline logoCONMED Co. (CNMD) Plans $0.20 Quarterly Dividend - May 24 at 12:30 PM logoETFs with exposure to CONMED Corp. : May 18, 2017 - May 18 at 4:20 PM logoDaniel Jonas Sells 3,000 Shares of CONMED Co. (CNMD) Stock - May 16 at 1:20 PM logoCONMED Co. (CNMD) Expected to Announce Earnings of $0.42 Per Share - May 5 at 11:19 AM logoCONMED (CNMD) Getting Positive News Coverage, Report Finds - May 4 at 6:26 PM logoETFs with exposure to CONMED Corp. : May 2, 2017 - May 2 at 7:28 PM logoCONMED (CNMD) Earning Somewhat Negative Media Coverage, Analysis Shows - May 1 at 4:42 PM logoCONMED Corp. :CNMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 1, 2017 - May 1 at 4:21 PM logoNeedham & Company LLC Boosts CONMED Co. (CNMD) Price Target to $54.00 - April 30 at 12:44 PM logoCONMED Co. (CNMD) Lifted to Hold at Zacks Investment Research - April 29 at 2:03 PM logoCONMED (CNMD) Receiving Somewhat Favorable Press Coverage, Study Finds - April 28 at 5:58 PM logoLeerink Swann Weighs in on CONMED Co.'s Q3 2017 Earnings (CNMD) - April 28 at 1:54 PM logoKeyCorp Weighs in on CONMED Co.'s Q2 2017 Earnings (CNMD) - April 28 at 10:41 AM logoEdited Transcript of CNMD earnings conference call or presentation 26-Apr-17 8:30pm GMT - April 27 at 11:39 AM logoCONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y - April 27 at 11:39 AM logoCONMED Co. (CNMD) Stock Rating Lowered by Ladenburg Thalmann Financial Services - April 27 at 9:22 AM logoCONMED Co. (CNMD) Releases Earnings Results, Beats Estimates By $0.03 EPS - April 26 at 10:26 PM logoConmed reports 1Q loss - April 26 at 10:17 PM logoCONMED Co. (CNMD) Releases FY17 Earnings Guidance - April 26 at 7:46 PM logoCONMED Corporation Announces First Quarter 2017 Financial Results - April 26 at 5:17 PM logoCONMED (CNMD) Receives Daily Coverage Optimism Rating of 0.36 - April 25 at 2:12 PM logoCONMED (CNMD) Receives News Sentiment Rating of 0.41 - April 21 at 5:08 PM logoCONMED Corporation to Present at the Deutsche Bank 42nd Annual Health Care Conference - April 19 at 4:24 PM logoCONMED (CNMD) Earns News Sentiment Score of 0.56 - April 18 at 10:21 AM logoZacks: Analysts Anticipate CONMED Co. (CNMD) to Announce $0.34 Earnings Per Share - April 14 at 9:24 AM logoJury Awards $10 Million In Punitive Damages Against SurgiQuest, A Subsidiary Of CONMED Corporation For False Advertising In Dispute With Lexion Medical - April 13 at 4:25 PM logoCONMED Corporation Announces Jury Verdict in Delaware Litigation Against SurgiQuest - April 11 at 9:29 PM logoCONMED Corp. : CNMD-US: Dividend Analysis : March 15th, 2017 (record date) : By the numbers : April 6, 2017 - April 7 at 9:06 AM logoCONMED Corporation to Announce First Quarter 2017 Financial Results on April 26, 2017 - April 7 at 9:05 AM logoCONMED Corporation Announces Annual Meeting of Shareholders - March 7 at 4:23 PM logoCONMED CORP Files SEC form 10-K, Annual Report - March 1 at 8:13 AM logoEdited Transcript of CNMD earnings conference call or presentation 1-Feb-17 9:30pm GMT - February 2 at 9:49 PM logoCONMED's (CNMD) CEO Curt Hartman on Q4 2016 Results - Earnings Call Transcript - February 2 at 2:44 AM logoQ4 2016 Conmed Corp Earnings Release - After Market Close - February 1 at 4:42 PM logoCONMED Corporation Announces Fourth Quarter and Fiscal Year 2016 Financial Results - February 1 at 4:42 PM logoConmed Corp Earnings Call scheduled for 4:30 pm ET today - February 1 at 4:42 PM logoCONMED Corporation to Present at the Leerink Partners 6th Annual Global Healthcare Conference - January 26 at 5:29 PM logoCONMED Corp.: Get Out - January 25 at 10:34 PM logoBovie Medical up 6% premarket on CONMED deal for PlazXact Ablator - January 19 at 9:38 AM logoCONMED Corporation to Announce Fourth Quarter and Fiscal Year 2016 Financial Results on February 1, 2017 - January 17 at 5:14 PM logoCONMED Corporation to Present at the J.P. Morgan Healthcare Conference - December 22 at 4:32 PM logoConmed (CNMD) Passes Through 2% Yield Mark - November 10 at 10:45 AM logoCONMED CORP Financials - November 3 at 3:48 PM logoCONMED (CNMD) Q3 Earnings Meet Estimates, Improve Y/Y - October 31 at 10:16 AM logoCONMED Corporation Announces Third Quarter 2016 Financial Results - October 27 at 9:50 PM logoConmed Corp. Reveals 9% Increase In Q3 Earnings - October 27 at 9:50 PM logoCONMED CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits - October 27 at 4:36 PM logoQ3 2016 Conmed Corp Earnings Release - After Market Close - October 27 at 8:51 AM



CONMED (CNMD) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by Staff